Neuropsychopharmacology
October 1, 2020
Kirsten C. S. Adam, Manoj K. Doss, Elisa Pabon et al.
2 citations
With the increasing prevalence of legal cannabis use and availability, there is an urgent need to identify cognitive impairments related to its use. It is widely believed that cannabis, or its main psychoactive component Δ9-tetrahydrocannabinol (THC), impairs working memory, i.e., the ability to temporarily hold information in mind. However, our review of the literature yielded surprisingly...
Biological Psychiatry
September 29, 2020
M. H. Mejia, N. Wade, Rachel E. Baca et al.
Accumulating evidence suggests that the use of cannabis and nicotine and tobacco-related products (NTPs) during the adolescent years has harmful effects on the developing brain. Yet, few studies have focused on the developing brain as it relates to the co-administration of cannabis and NTPs, despite the high prevalence rates of co-use in adolescence. The review aimed to synthesize the existing...
Farmacja Polska
September 28, 2020
Agata Tadeja
1 citation
Research on using drugs in medicine was almost completely stopped and delegalized in 1971, by Convention on Psychotropic Substances. Most of studies carried out before 1971 were methodologically inappropriate according to current research methodologies, yet it was proven that there is some potential in using substances like lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine,...
Journal of Cannabis Research
September 22, 2020
Petter Grahl Johnstad
29 citations
BACKGROUND: While cannabis has a long history of spiritual use, its normalization in Western societies during the last decades has led to more recreational use. This study aimed to explore the characteristics of spiritual cannabis use as compared to recreational use and to the use of psychedelics such as LSD and psilocybin. METHODS: The study employed a mixed methods research design that...
Cureus
September 8, 2020
Garrett Rossi, Melanie Beck
4 citations
A patient presented to the emergency department with his brother due to recent onset of paranoid behavior that escalated over the past month. The patient endorsed paranoid delusions of people watching him and following him in a black truck. The patient admitted to being unable to sleep for the past two weeks and to having hypervigilant behavior whenever he leaves the house. Due to the patient's...
Neuropsychopharmacology Reports
September 7, 2020
Toshihiko Matsumoto, Toshitaka Kawabata, Kyoji Okita et al.
9 citations
AIM: The objective of the current study was to identify risk factors that affect the onset of dependence and chronic psychosis due to cannabis use. METHODS: We examined clinical genetic factors, psychiatric disorders prior to cannabis use, starting age of cannabis use, duration and frequency of cannabis use, types of cannabis products used, combined use of other psychoactive substances, and the...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
September 2, 2020
K. Gicas, Alex Y T Cheng, William J. Panenka et al.
Longitudinal studies of cannabis exposure during early adolescence in the general population frequently report an increased risk of subsequently developing psychotic symptoms or a psychotic illness. However, there is a dearth of knowledge about the effects of early cannabis exposure on psychosis in homeless and precariously housed adults, who represent a population afflicted with high rates of...
Dialogues in Clinical Neuroscience
September 1, 2020
M. Crocq
This article retraces the story of cannabis from the earliest contacts of humans with the plant to its subsequent global expansion, its medicinal uses, and the discovery of the endocannabinoid system in the 20th century. Cannabis was attested to around 12 000 years ago near the Altai Mountains in Central Asia, and since then, cannabis seeds have accompanied the migration of nomadic peoples....
Journal of Affective Disorders
September 1, 2020
Emily M LaFrance, Nicholas C. Glodosky, Marcel O Bonn-Miller et al.
Many individuals use cannabis to manage symptoms of post-traumatic stress disorder (PTSD), and evidence indicates that the endocannabinoid system represents a viable target for treating these symptoms. Data from 404 medical cannabis users who self-identified as having PTSD were obtained from Strainprint®, a medical cannabis app that patients use to track changes in symptoms as a function of...
Dialogues in Clinical Neuroscience
September 2020
Paul D. Morrison, Robin Murray
Cannabis can elicit an acute psychotic reaction, and its long-term use is a risk factor for schizophrenia. The main active psychoactive ingredient ∆9-tetrahydrocannabinol (Δ9-THC) activates cannabinoid 1 (CB1) receptors, which are localized to the terminals of glutamate and GABA neurons in the brain. The endogenous cannabinoids are involved in information processing and plasticity at synapses...